Antigenics files Oncophage for EU approval in kidney cancer
This article was originally published in Scrip
Executive Summary
Antigenics has submitted a marketing authorisation application to the EMEArequesting approval of its therapeutic kidney cancer vaccine, Oncophage (HSPPC-96; vitespen), as an adjuvant treatment in the disease, under the conditional authorisation provision.